Aveo Eyes Role For Tivozanib In US Kidney Cancer Market, Against The Odds
In the Phase III TIVO-3 study, tivozanib is associated with a trend toward adverse survival and trial has missing data issues.
You may also be interested in...
Keeping Track: Oncology Submissions From Blueprint, Y-mAbs, BMS/bluebird; Approvals For BMS’ Reblozyl, LFB’s SevenFact
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Two successful Phase III studies of Inlyta in combination with two distinct immunotherapies, including its own, Merck KGaA-partnered Bavencio, puts Pfizer in a very strong position in the advanced kidney cancer market.
Novartis has walked away from Aveo’s cachexia candidate after a turbulent week in the development of the antibody program, three years after paying $15m for development and commercialization rights.